Agenda – April 15, 2020 NOTE: The Board may rearrange its agenda to accommodate the Board or Members of the public.

Page 1 of 2

Oregon Board of Pharmacy BOARD MEETING AGENDA

Meeting Location: Teleconference* *877-873-8017 Participant code: 139360

Wednesday, April 15, 2020 8:30 AM

The Oregon Board of Pharmacy serves to promote and protect public health, safety, and welfare by ensuring high standards in the practice of pharmacy and through effective regulation of the

manufacture and distribution of drugs.

WEDNESDAY, April 15, 2020 8:30 AM*

I. OPEN SESSION, Cyndi Vipperman, CPhT, Presiding

a. Roll Call b. Agenda Review and Approval Action Necessary

II. EXECUTIVE SESSION – NOT OPEN TO THE PUBLIC, pursuant to ORS 676.165, 676.175, ORS 192.660 (1) (2)

(f) (L). 8:40AM a. Deliberation on Disciplinary Cases and Investigations b. Legal Advice pursuant to ORS 192.660(2)(f)

III. Contested Case Deliberation pursuant to ORS 192.690(1) – Not open to the public

IV. OPEN SESSION – This is scheduled to begin at 11:00 AM*

a. Introduction and Installation of new Board Members - Vipperman i. Nichole Watson, Public Member; and ii. Mishele Dufour, Pharmacy Technician Member

Due to the COVID-19 State of Emergency and Governor Brown’s Executive Order 20-12, the Oregon Board of Pharmacy office will be closed to protect the public and our employees, effective immediately and until further notice. The April

meeting of the Oregon Board of Pharmacy will be held via teleconference.

Please contact Karen MacLean at Karen.S.MacLean@oregon.gov by Tuesday, April 14, 2020 at 2:00pm to let us know if you plan to listen to the Board’s discussion in Open Session to facilitate this meeting effectively. All individuals from the public who participate during Open Session will be asked to identify themselves on the call and email to confirm your attendance.

• All Board meetings except Executive or Closed Sessions are open to the public. Pursuant to ORS 192.660, Executive

Sessions are closed, with the exception of news media and public officials. • No final actions will be taken in Executive Session. • When action is necessary, the Board or Committee will return to an open Public Meeting.

For additional information, please contact Karen MacLean.

≈ The meeting location is accessible to persons with disabilities. A request for hearing impaired assistance and

accommodations for persons with disabilities should be made to Karen MacLean at 971-673-0001 at least 48 hours prior to the meeting. ≈

Agenda – April 15, 2020 NOTE: The Board may rearrange its agenda to accommodate the Board or Members of the public.

Page 2 of 2

V. GENERAL ADMINISTRATION a. COVID-19 update - Schnabel b. Rules

i. Consider sending rules to Rulemaking Hearing – Karbowicz 1. Div 080 – Schedule I additions #A Action Necessary 2. Div 041 – Prescription Reader Accessibility #A1 Acton Necessary

c. Public Health and Pharmacy Formulary Advisory Committee update - Karbowicz i. Committee Meeting and Recommendations update #B

d. Motions related to Disciplinary Actions – Efremoff Action Necessary

VI. ISSUES AND ACTIVITIES* a. Financial/Budget Report - #C-C1 Schnabel/MacLean

i. 2021-23 Policy Packages for consideration ii. Key Performance Measures (KPM) proposed revisions #C3

VII. Approve Consent Agenda* Action Necessary

*Items listed under the consent agenda are considered to be routine agency matters and will be approved by a single motion of the Board without separate discussion. If separate discussion is desired, that item will be removed from the consent agenda and placed on the regular business agenda.

a. NAPLEX Scores – September 1-December 31, 2019 CONSENT-1 CONFIDENTIAL b. MPJE Scores – September 1-December 31, 2019 CONSENT-2 CONFIDENTIAL c. License/Registration Ratification January 23, 2020 – April 7, 2020 - CONSENT-3 d. Pharmacy Technician Extensions – none e. Board Minutes – February 5-6, 2020 – CONSENT-4

Adjourn Action Necessary

Oregon Board of Pharmacy Division 080 – Clonazolam/Benzo 4.2020

Revisions to Division 080 – Controlled Substances are provided to address an immediate public 1 safety concern related to benzodiazepine overdoses reported in Portland, Oregon and Idaho. 2

3

Chapter 855 4

Division 80 5 SCHEDULE OF CONTROLLED SUBSTANCES 6

7

855-080-00218 Schedule I 9

(1) Schedule I consists of the drugs and other substances, by whatever official, common, usual,10 chemical, or brand name designated, listed in 21CFR part 1308.11, and unless specifically 11 excepted or unless listed in another schedule, any quantity of the following substances, including 12 their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence 13 of such isomers, esters, ethers, and salts is possible within the specific chemical designation: 14

(a) 1,4-butanediol;15

(b) Gamma-butyrolactone16

(c) Methamphetamine, except as listed in OAR 855-080-0022;17

(d) Dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide (U-47700)18

(e) 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]piperidin-2-ylidene]benzenesulfonamide (W-18) and19 positional isomers thereof, and any substituted derivative of W-18 and its positional isomers, and 20 their salts, by any substitution on the piperidine ring (including replacement of all or part of the 21 nitrophenylethyl group), any substitution on or replacement of the sulfonamide, or any 22 combination of the above that are not FDA approved drugs, unless specifically excepted or when 23 in the possession of an FDA registered manufacturer or a registered research facility, or a person 24 for the purpose of sale to an FDA registered manufacturer or a registered research facility. 25

(f) Substituted derivatives of cathinone and methcathinone that are not listed in OARs 855-080-26 0022 through 0026 (Schedules II through V) or are not FDA approved drugs, including but not 27 limited to, 28

(A) Methylmethcathinone (Mephedrone);29

(B) Methylenedioxypyrovalerone (MDPV);30

(C) Methylenedioxymethylcathinone (Methylone);31

(D) 2-Methylamino-3’,4’-(methylenedioxy)-butyrophenone (Butylone);32

(E) Fluoromethcathinone (Flephedrone);33

APRIL 2020 / A

Oregon Board of Pharmacy Division 080 – Clonazolam/Benzo 4.2020

(F) 4-Methoxymethcathinone (Methedrone). 34

(2) Schedule I also includes any compounds in the following structural classes (2a–2k) and their 35 salts, that are not FDA approved drugs, unless specifically excepted or when in the possession of 36 an FDA registered manufacturer or a registered research facility, or a person for the purpose of 37 sale to an FDA registered manufacturer or a registered research facility: 38

(a) Naphthoylindoles: Any compound containing a 3-(1-naphthoyl)indole structure with 39 substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole 40 ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of 41 this structural class include but are not limited to: JWH-015, JWH-018, JWH-019, JWH-073, 42 JWH-081, JWH-122, JWH-200, JWH-210, AM-1220, MAM-2201 and AM-2201; 43

(b) Phenylacetylindoles: Any compound containing a 3-phenylacetylindole structure with 44 substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole 45 ring to any extent, whether or not substituted in the phenyl ring to any extent. Examples of this 46 structural class include but are not limited to: JWH-167, JWH -201, JWH-203, JWH-250, JWH-47 251, JWH-302 and RCS-8; 48

(c) Benzoylindoles: Any compound containing a 3-(benzoyl)indole structure with substitution at 49 the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any 50 extent and whether or not substituted in the phenyl ring to any extent. Examples of this structural 51 class include but are not limited to: RCS-4, AM-694, AM-1241, and AM-2233; 52

(d) Cyclohexylphenols: Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure 53 with substitution at the 5-position of the phenolic ring whether or not substituted in the 54 cyclohexyl ring to any extent. Examples of this structural class include but are not limited to: CP 55 47,497 and its C8 homologue (cannabicyclohexanol); 56

(e) Naphthylmethylindoles: Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane 57 structure with substitution at the nitrogen atom of the indole ring whether or not further 58 substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to 59 any extent; 60

(f) Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole structure with 61 substitution at the nitrogen atom of the pyrrole ring whether or not further substituted in the 62 pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent; 63

(g) Naphthylmethylindenes: Any compound containing a 1-(1-naphthylmethyl) indene structure 64 with substitution at the 3-position of the indene ring whether or not further substituted in the 65 indene ring to any extent and whether or not substituted in the naphthyl ring to any extent; 66

(h) Cyclopropanoylindoles: Any compound containing an 3-(cyclopropylmethanoyl)indole 67 structure with substitution at the nitrogen atom of the indole ring, whether or not further 68 substituted in the indole ring to any extent and whether or not substituted in the cyclopropyl ring 69

APRIL 2020 / A

Oregon Board of Pharmacy Division 080 – Clonazolam/Benzo 4.2020

to any extent. Examples of this structural class include but are not limited to: UR-144, XLR-11 70 and A-796,260; 71

(i) Adamantoylindoles: Any compound containing a 3-(1-adamantoyl)indole structure with 72 substitution at the nitrogen atom of the indole ring, whether or not further substituted in the 73 indole ring to any extent and whether or not substituted in the adamantyl ring to any extent. 74 Examples of this structural class include but are not limited to: AM-1248 and AB-001; 75

(j) Adamantylindolecarboxamides: Any compound containing an N-adamantyl-1-indole-3-76 carboxamide with substitution at the nitrogen atom of the indole ring, whether or not further 77 substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring 78 to any extent. Examples of this structural class include but are not limited to: STS-135 and 79 2NE1; and 80

(k) Adamantylindazolecarboxamides: Any compound containing an N-adamantyl-1-indazole-3-81 carboxamide with substitution at the nitrogen atom of the indazole ring, whether or not further 82 substituted in the indazole ring to any extent and whether or not substituted in the adamantyl ring 83 to any extent. Examples of this structural class include but are not limited to: AKB48. 84

(3) Schedule I also includes any other cannabinoid receptor agonist that is not listed in OARs 85 855-080-0022 through 0026 (Schedules II through V) or is not an FDA approved drug. 86

(4) Schedule I also includes any substituted derivatives of fentanyl that are not listed in OARs 87 855-080-0022 through 0026 (Schedules II through V) or are not FDA approved drugs, and are 88 derived from fentanyl by any substitution on or replacement of the phenethyl group, any 89 substitution on the piperidine ring, any substitution on or replacement of the propanamide group, 90 any substitution on the phenyl group, or any combination of the above. 91

(5) Schedule I also includes any compounds in the following structural classes (a – b), and 92 their salts, that are not listed in OARs 855-080-0022 through 0026 (Schedules II through V) 93 or FDA approved drugs, unless specifically excepted or when in the possession of an FDA 94 registered manufacturer or a registered research facility, or a person for the purpose of 95 sale to an FDA registered manufacturer or a registered research facility: 96

(a) Benzodiazepine class: A fused 1,4-diazepine and benzene ring structure with a phenyl 97 connected to the diazepine ring, with any substitution(s) or replacement(s) on the 1,4-98 diazepine or benzene ring, any substitution(s) on the phenyl ring, or any combination 99 thereof. Examples of this structural class include but are not limited to: Clonazolam, 100 Flualprazolam 101

(b) Thienodiazepine class: A fused 1,4-diazepine and thiophene ring structure with a 102 phenyl connected to the 1,-4-diazepine ring, with any substitution(s) or replacement(s) on 103 the 1,4-diazepine or thiophene ring, any substitution(s) on the phenyl ring, or any 104 combination thereof. Examples of this structural class include but are not limited to: 105 Etizolam 106

APRIL 2020 / A

Oregon Board of Pharmacy Division 080 – Clonazolam/Benzo 4.2020

(5) (6) Exceptions. The following are exceptions to subsection (1) of this rule: 107

(a) 1, 4-butanediol and gamma-butyrolactone when in the possession of a person for the purpose 108 of its sale to a legitimate manufacturer of industrial products and the person is in compliance 109 with the Drug Enforcement Administration requirements for List I Chemicals; 110

(b) 1, 4-butanediol and gamma-butyrolactone when in the possession of a person for the purpose 111 of the legitimate manufacture of industrial products; 112

(c) Marijuana and delta-9-tetrahydrocannabinol (THC). 113

Statutory/Other Authority: ORS 689.205 114 Statutes/Other Implemented: ORS 475.035, 475.059 & 475.065 115

APRIL 2020 / A

Oregon Board of Pharmacy April 2020

In December 2019, the Board adopted temporary rule OAR 855-041-1131 to address directives 1 of 2019 HB 2935 which require accessibility services for visually impaired patients. These rules 2 are intended for all prescription drugs dispensed directly to patients, and requirements apply to 3 pharmacies and dispensing drug outlets, including non-resident pharmacies. 4

5

Impacts: In Oregon, it is estimated that 104,500 patients are visually impaired 6

Justification: Operative date is January 1, 2020 7

Documents relied upon include: Title VI of the Civil Rights Act of 1964 (42 USC 2000d) 8

9

OAR 855-041-1131 Prescription Reader Accessibility 10

11

A pharmacy shall notify each person to whom a prescription drug is dispensed that a 12

prescription reader is available to the person upon request; a prescription reader is a 13

device designed to audibly convey labeling information. A pharmacy that provides a 14

prescription reader shall make it available to the person for at least the duration of the 15

prescription, shall confirm it is appropriate to address the person’s visual impairment, and 16

shall ensure that prescription labels are compatible with the prescription reader. This 17

requirement does not apply to an institutional drug outlet, dispensing a drug intended for 18

administration by a healthcare provider. 19

20

Statutory/Other Authority: ORS 689.205 21

Statutes/Other Implemented: 2019 OL Ch 438 22

APRIL 2020 / A1

PHPFAC Minutes – March 6, 2020

MINUTES

Public Health and Pharmacy Formulary Advisory Committee Meeting March 6, 2020, 8:30am

Portland State Office Building, 800 NE Oregon St. Portland, OR 97232 Conference Room 1D

Committee Members Evon Anukam, RPh Amy Burns, RPh Kat Chinn, RN MSN - excused Sean Jones, MD Amy Valdez, RPh

OBOP Staff to Committee Joe Schnabel, Executive Director Fiona Karbowicz, Pharmacist Consultant Rachel Melvin, Operations Policy Analyst

Mark Helm, MD Helen Turner, DNP

Karen MacLean, Administrative Director Brianne Efremoff, Compliance Director Cassie Ricketts, Office Manager

Agenda Item Desired Outcome

Welcome Roll call

Agenda review and approvalMotion to approve agenda was made and unanimously carried (Motion by Burns, second by Jones).

11.20.19 Minutes review and approvalMotion to approve 11/20/19 Minutes was made and unanimously carried (Motion by Jones, second by Anukam).

Committee Business High Priority and Housekeeping Items

Reappointments and Officer Selection. Executive Director Joe Schnabel reported an update from the Governor’s office, regarding reappointments of Committee members. About half of the Committee members have been reappointed for a full 2-year term, while the others have been reappointed for a 1-year term, with the option to serve for an additional term after, as a method to stagger Committee membership moving forward.

Selection of 2020 Officers. Committee Chair Amy Valdez asked the Committee members if anyone was interested in serving the Committee as chair/vice-chair.

Motion to select Amy Valdez, as Chair and Mark Helm as Vice Chair was made and unanimously carried. Motion for Chair by Amy Burns, seconded by Evon Anukam, Motion to nominate Vice Chair by Amy Burns, seconded by Sean Jones.

OBOP 2020-2024 Strategic Plan. Schnabel provided a brief overview of the Board’s plan, initiated in November 2019 and finalized at the Board’s February 2020 meeting. The five goal areas (or strategic priorities) are: Technicians, Technology, Licensing, Regulation, and Communication. It is expected that the final Plan will be published in the upcoming weeks.

2019-2021 OBOP Affirmative Action/Diversity & Inclusion Plan, Policy and Training. Schnabel shared an overview of and how to access the agency’s Affirmative Action plan and policy. He provided training to the Committee, reviewing the New York Times, The Upshot, The New Healthcare, January 13, 2020 article, Race and Medicine: The Harm that Comes from Mistrust: Racial Bias Still Affects Many Aspects of Health Care. Joe shared his insights on the article

APRIL 2020 / B

PHPFAC Minutes – March 6, 2020

regarding healthcare disparities and current realities for minorities as well as shared a personal story about the article, describing the nexus of Native American tribal healthcare disparities to the US Civil Rights Act of 1964. Committee members appreciated the training and opportunity to learn.

2020 Mandatory State of Oregon Training. Karen reminded Committee members of the requirement to complete the newly distributed iLearn trainings that need to be completed online by September 30, 2020.

Committee Protocol Development

PrEP – HIV Preventative Pre-Exposure Prophylaxis

Fiona gave a brief overview of 2020 HB 4116 and its background and intersection to Committee/OBOP efforts. The bill is not expected to pass.

SME: Geoffrey L’Heureux reviewed the HIV preventative PrEP patient self-screening intake form and protocol.

The Committee discussed edits and enhancements to the intake form/questionnaire, working to strike a balance between helpful information versus extemporaneous to assist in the pharmacist’s proactive screening process and determination of whether additional tests might be needed, including STIs.

After lengthy Committee deliberation related to such issues as presence of underlying medical conditions of patients, Oregon pharmacist’s inhibited legal ability to order labs, and the staffing realities of retail pharmacies, the following elements were determined:

• Any patient seeking PrEP from an Oregon pharmacy will first need to meet the following documented inclusion criteria:

o Negative HIV status, confirmed with a 4th generation antibody/antigen (<14 days)

o Baseline STI testing: Gonorrhea, Chlamydia, Syphilis, and HepB sAg negative (this may include proof of vaccination per ALERT IIS, completed and appropriately timed series)

o Baseline renal function: via estimated GFR/creatinine clearance

Informs prescribing criteria: greater than (>) 30mL/min (Descovy) or >50mL/min (Truvada)

o Patient attestation of avoiding risky sexual activities 14 days prior to and after HIV test

• Exclusion criteria:

o Positive or indeterminate HIV status

o Positive HepB sAg

• Prescribing criteria (delineate between initial and ‘refills’):

o (FDA approved recommended regimen) Use recommended product selections, including adherence to FDA package insert labeling, #90 day rx increments; and

o HIV negative status confirmed q 3 months

o Renal confirmation at 3 months, and every 6 months ongoing

o STI ongoing with each refill (q 3 months or q 6 months as CDC recommends)

o Counseling points / AVS: pregnancy prevention / partner therapy; consider contraceptive co-prescribing

APRIL 2020 / B

PHPFAC Minutes – March 6, 2020

Committee requested that L’Heureux incorporate these elements into updated versions of the patient intake form and prescribing guidelines. Same education recommendation as for PEP (a comprehensive training program related to pharmacist prescribing of HIV prevention medications, to include related trauma informed care)

No motion at this time; bring back to next available meeting for review.

VVC – Vulvovaginal Candidiasis

SMEs: Natasha Malik and Jackie Foster reviewed the VVC patient self-screening intake form and treatment care plan (“protocol package”).

Committee requested that SMEs incorporate minor edits into updated versions of the patient intake form and treatment care plan. The following elements were determined:

• Inclusion criteria: Non-complicated VVC

• Exclusion/referral criteria: Complicated VVC

• Prescribing parameters/Treatment care plan: 4 in a year threshold

• Specified pharmacist training/education: none required

MOTION to recommend the revised Vulvovaginal Candidiasis (VVC) Statewide Drug Therapy Management Protocol “package” to the Oregon Board for review. This includes adherence to elements outlined in OAR 855-020-0110 (core elements), use of standardized patient self-screening intake form, with corresponding assessment and treatment care pathway, prescribing parameters, and required follow-up, as revised. The Committee recommends that no additional education is needed. Motion made and unanimously carried (Motion by Helm, seconded by Turner).

Rules development / implementation update – Karbowicz

Karbowicz provided a rule implementation update. The Board had a first rule review at the February 2020 meeting. They discussed and appreciated the great work by the Committee members and SMEs during 2019 to develop the three protocol packages (Tobacco cessation, Travel medications, and PEP). Most discussion focused on the legalities related to adopting the associated rules. Emphasis was on the various education requirement options, such as requiring ACPE-only, and about the timing of CE and comprehensive training programs. Per legal counsel direction, the Board plans to adopt the “protocol packages” by reference. The rules are on track to go to rulemaking hearing in May 2020, for potential final adoption in June.

There were no new items to explore.

Upcoming Meeting Schedule (subject to change)

Meetings Scheduled

• April 1, 2020 – (brief conference call to approve minutes)

Is 6pm on Wednesdays still necessary?

September 11, 2020 – room 1D

• October 7, 2020 – (brief conference call to approve minutes)

Motion to adjourn at 2:14PM was made and unanimously carried (Motion by Turner, seconded by Burns). The Oregon Board of Pharmacy serves to promote and protect public health, safety, and welfare by ensuring high standards

in the practice of pharmacy and through effective regulation of the manufacture and distribution of drugs.

APRIL 2020 / B

BOARD OF PHARMACY Actuals through January 2020 month-end-closeAY21 CASH FLOWOF Appn 30235

LAB Rstars EBoard or AdjustedBudget ORBITS Financial Adj Budget or Financial ACTUALS UnobligatedObjects REVENUE & EXPENDITURES BUDGET Plan Salary Pot Plan To Date BalanceREVENUE

0205 Other Business Licenses 7,146,250 7,146,250 7,146,250 2,055,660 5,090,590 29%0210 Other NonBusiness Licenses and Fee 139,296 139,296 139,296 57,432 81,864 41%0505 Fines and Forfeits 405,000 405,000 405,000 159,415 245,585 39%0605 Interest and Investments 45,000 45,000 45,000 62,158 (17,158) 138%0975 Other Revenue 57,090 57,090 57,090 22,784 34,306 40%

SubTotal Revenue 7,792,636 7,792,636 0 7,792,636 2,357,448 5,435,188 30%TRANSFERS

2443 Transfer out to OHA--Workforce/PD (416,146) (416,146) (416,146) 0 (416,146) 0%SubTotal Transfers (416,146) (416,146) 0 (416,146) 0 (416,146) 0%

TOTAL REVENUE & TRANSFERS 7,376,490 7,376,490 0 7,376,490 2,357,448 5,851,334 32%

PERSONAL SERVICES3110 Regular Employees 3,663,668 3,663,668 3,663,668 968,024 2,695,644.10 26%

Board Member Stipends - - 0 - 3160 Temporary Appointments 26,180 26,180 26,180 5,149 21,031 20%3170 Overtime Payments - - 0 863 (863) 0%3180 Shift Differential - - 0 - - 0%3190 All Other Differential 190,428 190,428 190,428 64,684 125,744 34%3210 ERB Assessment 1,281 1,281 1,281 316 965 25%3220 Public Employees' Retirement Syste 647,442 647,442 647,442 161,651 485,791 25%3221 Pension Bond Contribution 200,306 200,306 200,306 58,737 141,569 29%3230 Social Security Tax 296,540 296,540 296,540 74,472 222,068 25%3240 Unemployment Assessment - - 0 - - 0%3250 Workers' Compensation Assessment 1,276 1,276 1,276 255 1,021 20%3260 Mass Transit Taxes 23,248 23,248 23,248 6,193 17,055 27%3270 Flexible Benefits 774,048 774,048 774,048 186,897 587,151 24%3465 Reconciliation Adjustment (20,653) 0 - - 0%

SubTotal Personal Services 5,803,764 5,824,417 - 5,824,417 1,527,240 4,297,177 26% 4,297,177$ SERVICES AND SUPPLIES Proj all

4100 InState Travel 113,572 113,572 113,572 19,123 94,449 17%4125 Out of State Travel 16,322 16,322 16,322 2,097 14,225 13%4150 Employee Training 21,400 21,400 21,400 7,699 13,701 36%4175 Office Expenses 129,018 129,018 129,018 15,992 113,026 12%4200 Telecommunications 48,830 48,830 48,830 10,434 38,396 21%4225 State Govt. Service Chgs. 163,176 163,176 163,176 75,308 87,868 46%4250 Data Processing 80,540 80,540 80,540 123,232 (42,692) 153%4275 Publicity & Publications 39,583 39,583 39,583 3,416 36,167 9%4300 Professional Services 321,394 321,394 321,394 77,695 243,699 24%4315 IT Professional Services 652,149 652,149 652,149 229,660 422,489 35%4325 Attorney General 551,381 551,381 551,381 196,511 354,870 36%4375 Employee Recruitment & Develop 653 653 653 - 653 0%4400 Dues & Subscriptions 5,195 5,195 5,195 865 4,330 17%4425 Facilities Rent & Taxes 210,941 210,941 210,941 59,230 151,711 28%4475 Facilities Maintenance 53 53 53 - 53 0%4525 Medical Supplies and Services 1,152 1,152 1,152 166 987 14%4575 Agency Program Related S&S 240,152 240,152 240,152 43,389 196,763 18%4650 Other Services & Supplies 284,656 284,656 284,656 79,230 205,426 28%4700 Expendable Property 13,526 13,526 13,526 - 13,526 0%4715 IT Expendable Property 43,363 43,363 43,363 2,578 40,785 6%5600 Data Processing Hardware 8,611 8,611 8,611 - 8,611 0%5900 Other Capital Outlay - - 0 - - 0%

SubTotal Services and Supplies 2,945,667 2,945,667 - 2,945,667 946,624 1,999,043 32% 1,999,043$ SPECIAL PAYMENTS

6085 Other Special Payments 12,447 12,447 12,447 - 12,447 0%6443 Special Payments to OHA-HPSP - - - - - 0%

SubTotal Transfers 12,447 12,447 0 12,447 0 12,447 0% 12,447$

Total Expenditures Budget 8,761,878 8,782,531 - 8,782,531 2,473,864 6,308,667 28% 6,308,667$ 7,057,070

LAB % PS 66% 66% Target 100%LAB % S&S 34% 34%LAB % SP 0% 0%

CashAY19 Ending Cash Balance 3,757,650Revenue less Expenditures ActualsTotal Revenue & Transfers 2,357,448Total Expenditures (2,473,864)Total Revenues & Transfers less Expenditures (116,416) (116,416)AY21 Cash Balance after the Fiscal Month Closed 3,641,234

Budgeted Revenues not yet received (zero) less Estimated Transfers to OHA-PMP & Workforce Data program to be mad 5,019,042 Revenue received is more than budgeted so zero is not yet receivedBudgeted Expenditures not yet spent (6,308,667) AY21 Estimated Cash Balance 2,351,609Cash Balance Contingency (Months) 6.43 months

% Expended

APRIL 2020 / C

BOARD OF PHARMACY Actuals through February 2020 month-end-closeAY21 CASH FLOWOF Appn 30235

LAB Rstars EBoard or AdjustedBudget ORBITS Financial Adj Budget or Financial ACTUALS UnobligatedObjects REVENUE & EXPENDITURES BUDGET Plan Salary Pot Plan To Date BalanceREVENUE

0205 Other Business Licenses 7,146,250 7,146,250 7,146,250 2,435,725 4,710,525 34%0210 Other NonBusiness Licenses and Fee 139,296 139,296 139,296 63,698 75,598 46%0505 Fines and Forfeits 405,000 405,000 405,000 168,085 236,915 42%0605 Interest and Investments 45,000 45,000 45,000 68,972 (23,972) 153%0975 Other Revenue 57,090 57,090 57,090 26,605 30,485 47%

SubTotal Revenue 7,792,636 7,792,636 0 7,792,636 2,763,086 5,029,550 35%TRANSFERS

2443 Transfer out to OHA--Workforce/PD (416,146) (416,146) (416,146) 0 (416,146) 0%SubTotal Transfers (416,146) (416,146) 0 (416,146) 0 (416,146) 0%

TOTAL REVENUE & TRANSFERS 7,376,490 7,376,490 0 7,376,490 2,763,086 5,445,696 37%

PERSONAL SERVICES3110 Regular Employees 3,663,668 3,663,668 3,663,668 1,111,239 2,552,429.49 30%

Board Member Stipends - - 0 - 3160 Temporary Appointments 26,180 26,180 26,180 5,149 21,031 20%3170 Overtime Payments - - 0 863 (863) 0%3180 Shift Differential - - 0 - - 0%3190 All Other Differential 190,428 190,428 190,428 73,913 116,515 39%3210 ERB Assessment 1,281 1,281 1,281 363 918 28%3220 Public Employees' Retirement Syste 647,442 647,442 647,442 185,876 461,566 29%3221 Pension Bond Contribution 200,306 200,306 200,306 66,977 133,329 33%3230 Social Security Tax 296,540 296,540 296,540 85,835 210,705 29%3240 Unemployment Assessment - - 0 - - 0%3250 Workers' Compensation Assessment 1,276 1,276 1,276 290 986 23%3260 Mass Transit Taxes 23,248 23,248 23,248 7,102 16,147 31%3270 Flexible Benefits 774,048 774,048 774,048 217,797 556,251 28%3465 Reconciliation Adjustment (20,653) 0 - - 0%

SubTotal Personal Services 5,803,764 5,824,417 - 5,824,417 1,755,402 4,069,015 30% 4,069,015$ SERVICES AND SUPPLIES Proj all

4100 InState Travel 113,572 113,572 113,572 20,712 92,860 18%4125 Out of State Travel 16,322 16,322 16,322 2,302 14,020 14%4150 Employee Training 21,400 21,400 21,400 7,805 13,595 36%4175 Office Expenses 129,018 129,018 129,018 16,595 112,423 13%4200 Telecommunications 48,830 48,830 48,830 11,264 37,566 23%4225 State Govt. Service Chgs. 163,176 163,176 163,176 76,839 86,337 47%4250 Data Processing 80,540 80,540 80,540 125,420 (44,880) 156%4275 Publicity & Publications 39,583 39,583 39,583 7,942 31,641 20%4300 Professional Services 321,394 321,394 321,394 89,283 232,111 28%4315 IT Professional Services 652,149 652,149 652,149 229,660 422,489 35%4325 Attorney General 551,381 551,381 551,381 196,553 354,828 36%4375 Employee Recruitment & Develop 653 653 653 - 653 0%4400 Dues & Subscriptions 5,195 5,195 5,195 1,780 3,415 34%4425 Facilities Rent & Taxes 210,941 210,941 210,941 67,692 143,249 32%4475 Facilities Maintenance 53 53 53 - 53 0%4525 Medical Supplies and Services 1,152 1,152 1,152 166 987 14%4575 Agency Program Related S&S 240,152 240,152 240,152 57,513 182,639 24%4650 Other Services & Supplies 284,656 284,656 284,656 87,896 196,760 31%4700 Expendable Property 13,526 13,526 13,526 - 13,526 0%4715 IT Expendable Property 43,363 43,363 43,363 2,578 40,785 6%5600 Data Processing Hardware 8,611 8,611 8,611 - 8,611 0%5900 Other Capital Outlay - - 0 - - 0%

SubTotal Services and Supplies 2,945,667 2,945,667 - 2,945,667 1,002,000 1,943,667 34% 1,943,667$ SPECIAL PAYMENTS

6085 Other Special Payments 12,447 12,447 12,447 - 12,447 0%6443 Special Payments to OHA-HPSP - - - - - 0%

SubTotal Transfers 12,447 12,447 0 12,447 0 12,447 0% 12,447$

Total Expenditures Budget 8,761,878 8,782,531 - 8,782,531 2,757,402 6,025,129 31% 6,025,129$ 7,057,070

LAB % PS 66% 66% Target 100%LAB % S&S 34% 34%LAB % SP 0% 0%

CashAY19 Ending Cash Balance 3,757,650Revenue less Expenditures ActualsTotal Revenue & Transfers 2,763,086Total Expenditures (2,757,402)Total Revenues & Transfers less Expenditures 5,684 5,684AY21 Cash Balance after the Fiscal Month Closed 3,763,333

Budgeted Revenues not yet received (zero) less Estimated Transfers to OHA-PMP & Workforce Data program to be mad 4,613,404 Revenue received is more than budgeted so zero is not yet receivedBudgeted Expenditures not yet spent (6,025,129) AY21 Estimated Cash Balance 2,351,609Cash Balance Contingency (Months) 6.43 months

% Expended

APRIL 2020 / C1

Legislatively Approved 2019 - 2021 Key Performance MeasuresPublished: 2/26/2019 2:06:52 PM

Agency: Pharmacy, Board of

Mission Statement:The mission of the Oregon State Board of Pharmacy is to promote, preserve and protect the public health, safety and welfare by ensuring high standards in the practice of pharmacy and by regulating the quality,manufacture, sale and distribution of drugs.

Legislatively Approved KPMs Metrics Agency Request Last Reported Result Target 2020 Target 2021

1. Percent of inspected pharmacies that are in compliance annually. Approved 82% 85% 85%2. Percent of audited pharmacists who complete continuing education ontime. Approved 96.40% 0% 95%

3. Percent of pharmacies inspected annually. Approved 100% 100% 100%4. Average number of days to complete an investigation from complaint toboard presentation. Approved 106 100 100

5. CUSTOMER SERVICE - Percent of Customers Rating Their SatisfactionWith the Agency’s Customer Service as “Good” or “Excellent” : OverallCustomer Service, Timeliness, Accuracy, Helpfulness, Expertise, andAvailability of Information.

Timeliness Approved 82% 90% 90%

Expertise 95% 95% 95%Accuracy 91% 90% 90%Helpfulness 91% 90% 90%Overall 91% 90% 90%Availability of Information 88% 90% 90%

6. Board Best Practices - Percent of total best practices met by the Board. Approved 100% 100% 100%

LFO Recommendation:

For KPM #2, LFO recommends the agency reports information only in odd number years when pharmacists renew their license and are audited.

For the remaining KPMs, LFO recommends approval of KPMs and targets as presented.

SubCommittee Action:

Approved LFO recommendation.

5 of 5

SB 5529 A

APRIL 2020 / C3